» Articles » PMID: 33323965

G9a Controls Pluripotent-like Identity and Tumor-initiating Function in Human Colorectal Cancer

Overview
Journal Oncogene
Date 2020 Dec 16
PMID 33323965
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal tumors are hierarchically organized and governed by populations of self-renewing cancer stem cells, representing one of the deadliest types of cancers worldwide. Emergence of cancer stemness phenotype depends on epigenetic reprogramming, associated with profound transcriptional changes. As described for pluripotent reprogramming, epigenetic modifiers play a key role in cancer stem cells by establishing embryonic stem-like transcriptional programs, thus impacting the balance between self-renewal and differentiation. We identified overexpression of histone methyltransferase G9a as a risk factor for colorectal cancer, associated with shorter relapse-free survival. Moreover, using human transformed pluripotent cells as a surrogate model for cancer stem cells, we observed that G9a activity is essential for the maintenance of embryonic-like transcriptional signature promoting self-renewal, tumorigenicity, and undifferentiated state. Such a role was also applicable to colorectal cancer, where inhibitors of G9a histone methyltransferase function induced intestinal differentiation while restricting tumor-initiating activity in patient-derived colorectal tumor samples. Finally, by integrating transcriptome profiling with G9a/H3K9me2 loci co-occupancy, we identified the canonical Wnt pathway, epithelial-to-mesenchyme transition, and extracellular matrix organization as potential targets of such a chromatin regulation mechanism in colorectal cancer stem cells. Overall, our findings provide novel insights on the role of G9a as a driver of cancer stem cell phenotype, promoting self-renewal, tumorigenicity, and undifferentiated state.

Citing Articles

Super-enhancer-hijacking RBBP7 potentiates metastasis and stemness of breast cancer via recruiting NuRD complex subunit LSD1.

Xi Y, Wang R, Qu M, Pan Q, Wang M, Ai X J Transl Med. 2025; 23(1):266.

PMID: 40038738 PMC: 11877695. DOI: 10.1186/s12967-025-06270-3.


Immunohistochemical Profiling of Histone Modification Biomarkers Identifies Subtype-Specific Epigenetic Signatures and Potential Drug Targets in Breast Cancer.

Huo Z, Zhang S, Su G, Cai Y, Chen R, Jiang M Int J Mol Sci. 2025; 26(2).

PMID: 39859484 PMC: 11765579. DOI: 10.3390/ijms26020770.


G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications.

Ni Y, Shi M, Liu L, Lin D, Zeng H, Ong C Cancers (Basel). 2024; 16(12).

PMID: 38927881 PMC: 11201431. DOI: 10.3390/cancers16122175.


The Role and Mechanism of the Histone Methyltransferase G9a in Tumors: Update.

Zhou H, Gui J, Zhu L, Mi Y Onco Targets Ther. 2024; 17:449-462.

PMID: 38832355 PMC: 11146345. DOI: 10.2147/OTT.S451108.


Spheroids and organoids derived from colorectal cancer as tools for drug screening.

Ahmad Zawawi S, Salleh E, Musa M Explor Target Antitumor Ther. 2024; 5(2):409-431.

PMID: 38745769 PMC: 11090692. DOI: 10.37349/etat.2024.00226.


References
1.
Jung G, Hernandez-Illan E, Moreira L, Balaguer F, Goel A . Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020; 17(2):111-130. PMC: 7228650. DOI: 10.1038/s41575-019-0230-y. View

2.
Brenner H, Kloor M, Pox C . Colorectal cancer. Lancet. 2013; 383(9927):1490-1502. DOI: 10.1016/S0140-6736(13)61649-9. View

3.
OBrien C, Pollett A, Gallinger S, Dick J . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2006; 445(7123):106-10. DOI: 10.1038/nature05372. View

4.
Visvader J, Lindeman G . Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012; 10(6):717-728. DOI: 10.1016/j.stem.2012.05.007. View

5.
de Sousa E Melo F, Kurtova A, Harnoss J, Kljavin N, Hoeck J, Hung J . A distinct role for Lgr5 stem cells in primary and metastatic colon cancer. Nature. 2017; 543(7647):676-680. DOI: 10.1038/nature21713. View